Nicholas Company Inc. Cuts Holdings in AbbVie Inc. $ABBV

Nicholas Company Inc. trimmed its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 12.7% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 38,725 shares of the company’s stock after selling 5,625 shares during the period. Nicholas Company Inc.’s holdings in AbbVie were worth $7,188,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Brighton Jones LLC boosted its stake in shares of AbbVie by 17.4% in the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after buying an additional 3,401 shares during the last quarter. Revolve Wealth Partners LLC boosted its stake in shares of AbbVie by 72.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after buying an additional 3,064 shares during the last quarter. Golden State Wealth Management LLC boosted its stake in shares of AbbVie by 4.6% in the 1st quarter. Golden State Wealth Management LLC now owns 2,124 shares of the company’s stock worth $445,000 after buying an additional 93 shares during the last quarter. Moody Aldrich Partners LLC boosted its stake in shares of AbbVie by 3.4% in the 1st quarter. Moody Aldrich Partners LLC now owns 3,103 shares of the company’s stock worth $650,000 after buying an additional 103 shares during the last quarter. Finally, Silver Oak Securities Incorporated boosted its stake in shares of AbbVie by 1.1% in the 1st quarter. Silver Oak Securities Incorporated now owns 6,184 shares of the company’s stock worth $1,270,000 after buying an additional 69 shares during the last quarter. 70.23% of the stock is owned by institutional investors.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 13,295 shares of the firm’s stock in a transaction dated Tuesday, August 5th. The stock was sold at an average price of $198.51, for a total transaction of $2,639,190.45. Following the sale, the executive vice president directly owned 58,247 shares of the company’s stock, valued at $11,562,611.97. This trade represents a 18.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Azita Saleki-Gerhardt sold 42,370 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total value of $8,407,055.40. Following the sale, the executive vice president directly owned 177,292 shares in the company, valued at approximately $35,178,278.64. This represents a 19.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.25% of the stock is owned by company insiders.

AbbVie Price Performance

NYSE:ABBV opened at $218.14 on Friday. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. The business’s 50-day simple moving average is $222.42 and its two-hundred day simple moving average is $200.94. The stock has a market cap of $385.35 billion, a PE ratio of 103.87, a P/E/G ratio of 1.42 and a beta of 0.51. AbbVie Inc. has a 52 week low of $163.81 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. The business had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The business’s quarterly revenue was up 9.1% on a year-over-year basis. During the same period last year, the firm earned $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. This is a boost from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a yield of 3.2%. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s payout ratio is 312.38%.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ABBV. Berenberg Bank raised AbbVie from a “hold” rating to a “buy” rating and raised their target price for the stock from $170.00 to $270.00 in a report on Wednesday, September 17th. Raymond James Financial reaffirmed an “outperform” rating and issued a $250.00 target price (up from $236.00) on shares of AbbVie in a report on Friday, October 17th. Evercore ISI raised their target price on AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a report on Monday, September 22nd. Wells Fargo & Company raised their target price on AbbVie from $240.00 to $260.00 and gave the stock an “overweight” rating in a report on Friday, September 12th. Finally, Guggenheim raised their target price on AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a report on Monday, October 20th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and an average price target of $234.80.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.